Diabetes and Antipsychotic Medications

---

The Diabetes and Antipsychotic Medications clinical education program presented by John W. Newcomer, MD, of Washington University in St. Louis, Missouri, explores the increased risk factors of diabetes in patients taking antipsychotic medications. The program is intended to broaden awareness and promote the prevention and early treatment of diabetes among psychiatric patients.

Coming Soon! Diabetes and Antipsychotic Medications Toolkit

The kit will include:

• A letter from the American Diabetes Association Program Planning Committee
• CD-ROMs which include an archived Webcast, professional tools and patient education tools
• A wall chart with the consensus on Antipsychotic Drugs and Obesity and Diabetes Monitoring Protocol

Pre-order your free professional toolkit today! Email your mailing address to Psychiatricpatientcep@diabetes.org. In order to ensure that you receive your tool kit, please send us a street address. No PO Boxes please.

Free continuing education credit will be available for physicians, psychologists, nurse practitioners, nurses, and pharmacists. For more information about this educational activity, contact Psychiatricpatientcep@diabetes.org.

---

Did You Know?

• The rate of type 2 diabetes in people diagnosed with schizophrenia is 2-4 times higher than the general population.




• Patients who take antipsychotic drugs for the treatment of a variety of mental illnesses may be at risk for obesity, diabetes, and high cholesterol.




• Experts recommend that patients who take antipsychotic drugs should receive appropriate baseline screening and ongoing monitoring.

---

Who Should Participate?

The Diabetes and Antipsychotic Medications clinical education program is designed specifically for psychiatrists, endocrinologists, primary care physicians, clinical psychologists, pharmacists, nurse practitioners, nurses and other interested health care professionals who treat patients with psychiatric illness, specifically schizophrenia.

This activity will help health care professionals who treat patients with diabetes understand the relationship between antipsychotic medications and diabetes, obesity, and cardiovascular disease. The seminar will address the challenges clinicians face, including the need to properly screen, counsel and monitor patients who are taking these drugs on an ongoing basis for metabolic complications.

---

Learning Objectives

At the end of this seminar participants will be able to:

• Explain why second-generation antipsychotic (SGA) medications may be more efficacious than first-generation antipsychotic (FGA) medications.
  
• Discuss the relationship of second-generation antipsychotic (SGA) drug use and obesity, prediabetes and type 2 diabetes.
  
• Compare differential effects of available SGA medications on psychiatric symptoms and medical endpoints.
  
• Implement evaluation and regular follow-up monitoring for patients taking SGA medication.
  
• List the variables associated with psychiatric illnesses that present challenges to improved patient outcomes.
  
• Refer patient to resources that will help in evaluating, teaching, and monitoring metabolic care.

---

Planning Committee

John W. Newcomer, MD, Chair and Speaker
Washington University
St. Louis, MO

John Devlin, MD
Maine Center for Diabetes
Scarborough, ME

Karen S. Flavin, RN
Washington University
St. Louis, MO

John Kane, MD
The Zucker Hillside Hospital
Glen Oaks, NY

James A. Levine, MD
Mayo Clinic
Rochester, MN

Pat Lustman, PhD
Washington University
St. Louis, MO

Nathaniel Clark, MD
American Diabetes Association
Alexandria, VA

This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb Company.